Revenue Cockpit
Helix Instruments · Helix Instruments · revenue-forecasting cockpit, as of 29 May 2026. Bottoms-up pipeline reconciled to a top-down model, priced as a closeable gap to plan.
I reconcile bottoms-up and top-down to $811.0M (±1.7%) — $29.0M short of your $840.0M plan.
You’re $29.0M short of the $840.0M plan — $24.0M you can fix, $5.0Myou can’t.
Close the $24.0M controllable and you land within $5.0M of plan — the rest is structural (FX, hard supply, calendar) and gets a band, not a lever.
Tracking $29.0M below plan through year-end — the wedge is the gap accumulating.
- re-weightedHelios Biosciences — channel−$159K
- slippedNorthwind Materials A — renewal−$149K
- slippedProbe Therapeutics E — channel−$66K
- re-weightedNimbus Systems C — channel−$63K
- slippedSentient Systems — channel−$59K
What the agent is flagging
Understand the build →Two-thirds of the gap is the consumables mix shift — and it is controllable.
Volume is healthy; realized margin is diluting as the book tilts to lower-margin consumables.
EMEA has run ~+6% optimistic three quarters running.
The EMEA commit is systematically high; I haircut it by 6% in the reconciled number.